References
- Kuhn R. The treatment of depressive states with an iminodibenzyl derivative (G 22355). Swiss Med. J.87, 1135–1140 (1957).
- Schildkraut JJ. The catecholamine hypothesis of affective disorders. Am. J. Psychiatry122, 509–522 (1965).
- Banerjee SP, Kung LS. Development of β-adrenergic receptor subsensitivity by antidepressants. Nature268, 455–456 (1977).
- Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science210, 88–90 (1980).
- Honegger UE, Disler B, Wiesmann UN. Chronic exposure of human cells in culture to the tricyclic antidepressant desipramine reduces the number of β-adrenoceptors. Biochem. Pharmacol.35, 1899–1902 (1986).
- Fishman PH, Finberg JP. Effect of the tricyclic antidepressant desipramine on β-adrenergic receptors in cultured rat glioma C6 cells. J. Neurochem.49, 282–289 (1987).
- Vetulani J, Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature257, 495–496 (1975).
- Baldessarini RJ. Current status of antidepressants: clinical pharmacology and therapy. J. Clin. Psychiatry50, 117–126 (1989).
- Banerjee SP, Kung LS. Development of β-adrenergic receptor subsensitivity by antidepressants. Nature268, 455–456 (1977).
- Wolfe BB, Harden TK, Sporn JR, Molinoff PB. Presynaptic modulation of β adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J. Pharmacol. Exp. Ther.207, 446–457 (1978).
- Hindmarch I. Expanding the horizons of depression: beyond the monoamine hypothesis. Hum. Psychopharmacol.16, 203–218 (2001).
- Li X, Huston E, Lynch MJ et al. Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293b2 cells and cardiac myocytes. Biochem. J.394, 427–435 (2006).
- Kientsch U, Burgi S, Ruedeberg C et al. St. John’s wort extract Ze 117 (Hypericum perforatum) inhibits norepinephrine and serotonin uptake into rat brain slices and reduces 3-adrenoceptor numbers on cultured rat brain cells. Pharmacopsychiatry34, 56–60 (2001).
- Donati RJ, Rasenick MM. G protein signaling and the molecular basis of antidepressant treatment. Life Sci.73, 1–17 (2003).
- Avissar S, Schreiber G. The involvement of G proteins in the pathogenesis and treatment of affective disorders. (Ziskind-Somerfeld Award Paper) Biol. Psychiatry31, 435–459 (1992).
- Avissar S, Schreiber G. Interaction of antibipolar and antidepressant treatments with receptor-coupled G proteins (Anna Monika Award Paper) Pharmacopsychiatry.25, 44–50 (1992).
- Shen C, Li H, Meller E. Repeated treatment with antidepressants differentially alters 5-HT(1A) agonist-stimulated [35S]-GTP gamma S binding in rat brain regions. Neuropharmacol.42, 1031–1038 (2002).
- Pejchal T, Foley MA, Kosofsky BE, Waeber C. Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [35S]-GTP gamma S autoradiography. Br. J. Pharmacol.135, 1115–1122 (1992).
- Sulser F. Antidepressant treatments and regulation of norepinephrine-receptor coupled adenylyl cyclase systems in brain. Adv. Biochem. Psychopharmacol.39, 249–261 (1984).
- Donati RJ, Thukral C, Rasenick MM. Chronic treatment of C6 Glioma cells with antidepressant drugs results in a redistribution of Gs. Mol. Pharmacol.59, 1426–1432 (2001).
- Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu. Rev. Biochem.67, 653–692 (1998).
- Palczewski K. GTP-binding-protein-coupled receptor kinases – two mechanistic models. Eur. J. Biochem.248, 261–9 (1997).
- Metaye T, Gibelin H, Perdrisot R, Kraimps JL. Pathophysiological roles of G-protein-coupled receptor kinases. Cell. Signal.17, 917–928 (2005).
- Stephen JP, Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol.12, 130–138 (2002).
- Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci.27, 107–144 (2004)
- Schulz R. The pharmacology of phosducin. Pharmacol. Res.43, 1–10 (2001).
- Muller S, Straub A, Schroder S et al. Interaction of phosducin with defined G protein βγ-subunits. J. Biol. Chem.271, 11781–11788 (1996).
- Thibault MW, Sganga MW, Miles MF. Interaction of Phosducin like protein with G protein βγ subunits. J. Biol.Chem.272, 12253–12256 (1997).
- Bauer PH, Lohse MJ. Effects of phosducin on the GTPase cycle of Go. Naunyn Schmiedebergs Arch. Pharmacol.357, 371–377 (1998).
- Berman DM, Kozasa T, Gilman AG. The GTPase-activating protein RGS4 stabilizes the transition state for nucleotide hydrolysis. J. Biol. Chem.271, 27209–27212 (1996).
- Niculescu AB, Segal DS, Kuczenski R. Identifying a serious of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol. Genomics9, 83–91 (2000).
- Barrett TB, Hauger RL, Kennedy JL et al. Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder. Mol. Psychiatry8, 546–547 (2003).
- Kelsoe JR, Spence MA, Loetscher E et al. A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22. Proc. Natl. Acad. Sci. USA.98, 585–590 (2001).
- Grange-Midroit M, Garcia-Sevilla JA, Ferrer-Alcon M et al. Regulation of GRK 2 and 6, β-arrestin-2 and associated proteins in the prefrontal cortex of drug-free and antidepressant drug-treated subjects with major depression. Brain Res. Mol. Brain Res.111, 31–41 (2003).
- Miralles A, Asensio VJ, Garcia-Sevilla JA. Acute treatment with the cyclic antidepressant desipramine, but not fluoxetine, increases membrane-associated G protein-coupled receptor kinases 2/3 in rat brain. Neuropharmacology43, 1249–57 (2002).
- Garcia-Sevilla JA, Ventayol P, Perez V et al. Regulation of platelet α2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology29, 580–588 (2004).
- Luttrell LM, Lefkowitz RJ. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci.115, 455–465 (2002).
- Gagnon AW, Kallal L, Benovic JL. Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the β2-adrenergic receptor. J. Biol. Chem.12, 6976–6981 (1998).
- Laporte SA, Oakley RH, Zhang J et al. The β2-adrenergic receptor/b-arrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc. Natl Acad. Sci. USA.96, 3712–3717 (1999).
- Zhang J, Barak LS , Winkler KE, Caron MG, Ferguson SSG. A central role for β-arrestins and clathrin-coated vesicle-mediated endocytosis in β2-adrenergic receptor resensitization. J. Biol. Chem.272, 27005–27014 (1997).
- Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol. Chem.274, 32248–32257 (1999).
- Lefkowitz RJ. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci.25, 413–422 (2004).
- Parruti G, Peracchia F, Sallese M et al. Molecular analysis of human β-arrestin-1: cloning, tissue distribution and regulation of expression. J. Biol. Chem.268, 9753–9761 (1993).
- Avissar S, Matuzany-Ruban A, Tzukert K, Schreiber G. β-arrestin-1 levels: reduced in leukocytes of patients with depression and elevated by antidepressants in rat brain. Am. J. Psychiatry161, 2066–2072 (2004).
- Matuzany-Ruban A, Avissar S, Schreiber G. Dynamics of β arrestin 1 protein and mRNA levels elevation by antidepressants in mononuclear leukocytes of patients with depression. J. Affect. Disord.88, 307–312 (2005).
- McDonald PH, Chow CW, Miller WE et al. β-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science290, 1574–1577 (2000).
- Luttrell LM, Roudabush FL, Choy EW et al. Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc. Natl. Acad. Sci.98, 2449–54 (2001).
- Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by β-arrestins. Science308, 512–517 (2005).
- Dwivedi Y, Rizavi HS, Roberts RC et al. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J. Neurochem.77, 916–928 (2001).
- Mercier G, Lennon AM, Renouf B et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J. Mol. Neurosci.24, 207–216 (2004).
- Kang J, Shi Y, Xiang B et al. A nuclear function of b arrestin 1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell123, 833–847 (2005).
- Scott MG, Le Rouzic E, Perianin A et al. Differential nucleocytoplasmic shuttling of b-arrestins. Characterization of a leucine-rich nuclear export signal in β-arrestin2. J. Biol. Chem.277, 37693–37701 (2002).
- Wang P, Wu Y, Ge X et al. Subcellular localization of β-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus.J. Biol. Chem.278, 11648–11653 (2003).
- Ahn S, Shenoy SK, Wei H, Lefkowitz RJ. Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J. Biol. Chem.279, 35518–35525 (2004).
- Beaulieu JM, Sotnikova TD, Marion S et al. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell122, 261–273 (2005).
- Beaulieu JM, Caron MG. β-arrestin goes nuclear. Cell123, 755–757 (2005).
- Morinobu S, Strausbaugh H, Terwilliger R, Duman RS. Regulation of c-Fos and NGF1-A by antidepressant treatments. Synapse25, 313–320 (1999).
- Dahmen N, Fehr C, Reuss S, Hiemke C. Stimulation of immediate early gene expression by desipramine in rat brain. Biol. Psychiatry42, 317–323 (1997).
- Morelli M, Pinna A, Ruiu S, Del Zompo M. Induction of Fos-like-immunoreactivity in the central extended amygdale by antidepressant drugs. Synapse31, 1–4 (1999).
- Slattery DA, Morrow JA, Hudson AL et al. Comparison of alterations in c-fos and Erg-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds. Neuropsychopharmacology30, 1278–1287 (2005).
- Miyata S, Hamamura T, Lee Y et al. Contrasting Fos expression induced by acute reboxetine and fluoxetine in the rat forebrain: neuroanatomical substrates for the antidepressant effect. Psychopharmacology177, 289–295 (2005).
- Kuipers SD, Trentani A, Westenbroek C et al. Unique patterns of FOS, phosphor-CREB and BrdU immunoreactivity in the female rat brain following chronic stress and citalopram treatment. Neuropharmacology50, 428–440 (2006).
- Chen TC, Wadsten P, Su S et al. The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21 and p27, resulting in growth inhibition, increased differentiation and subsequent apoptosis of malignant A-127 glioma cells. Cancer Biol. Ther.1, 268–276 (2002).
- Li X, Huston E, Lynch MJ et al. Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293b2 cells and cardiac myocytes. Biochem. J.394, 427–435 (2006).
- Schulz K, Danner S, Bauer P et al. Expression of phosducin in a phosducin-negative cell line reveals functions of a G bgamma-binding protein. J. Biol. Chem.271, 22546–22551 (1996).
- Pitcher JA, Inglese J, Higgins JB et al. Role of bγ subunits of G protein in targeting the β-adrenergic receptor kinase to membrane-bound receptor. Science257, 1264–1267 (1992).
- Garson J, Rodriguez-Diaz M, Lopez-Fando A et al. Glycosylated Phosducin like protein long regulates opioid receptor function in mouse brain. Neuropharmacology42, 813–828 (2002).
- Matuzany-Ruban A, Schreiber G, Farkash P, Avissar S. Phosducin like protein levels in leukocytes of patients with major depression and in rat cortex: The effect of chronic treatment with antidepressants. Psychiatry Res.141, 287–294 (2006).
- Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G protein signaling 4 (RGS4) expression in schizophrenia. Mol. Psychiatry6, 293–301 (2001).
- Brzustowics LM, Hodgkinson KA, Chow EW, Honer WG, Bassett AS. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science288, 678–682 (2000).
- Chowdari KV, Mirnics K, Semwal P et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum. Mol. Genet.11, 1373–1380 (2002).
- Chen X, Dunham C, Kendler S et al. Regulator of G-protein signaling 4 (RGS4) gene is associated with schizophrenia in Irish high density families. Am. J. Med. Genet. B. Neuropsychiatr. Genet.129, 23–26 (2004).
- Morris DW, Rodgers A, McGhee KA et al. Confirming RGS4 as a susceptibility gene for schizophrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet.125, 50–53 (2004).
- Williams NM, Preece A, Spurlock G et al. Support for RGS4 as a susceptibility gene for schizophrenia. Biol. Psychiatry55, 192–195 (2004).
- Avissar S, Schreiber G. Towards molecular diagnosis of mood disorders in psychiatry. Trends Mol. Med.8, 294–300 (2002).
- Carroll BJ. Dexamethasone suppression test: A review of contemporary confusion. J. Clin. Psychol.46, 13–20 (1985).
- Avissar S, Nechamkin Y, Roitman G, Schreiber G. Dynamics of ECT normalization of low G protein function and immunoreactivity in mononuclear leukocytes of patients with major depression. Am. J. Psychiatry155, 666–671 (1998).
- Avissar S, Schreiber G, Lam G et al. The effects of seasons and light therapy on G proteins levels in mononuclear leukocytes of patients with seasonal affective disorder. Arch. Gen. Psychiatry56, 178–183 (1999).
Website
- Psynomics brings the science of genomics to the field of psychiatry with revolutionary new tools to better manage bipolar disorder. www.psynomics.com